TNFRSF17 and Miyoshi myopathy: Recently, we published the short-term safety and initial efficacy [20,21] of a novel academic anti-BCMA CAR construct (namely, HBI0101), in a phase I clinical trial for the treatment of R/R MM patients (NCT04720313).